Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-11-08

Clinical Trial Update: Efficacy of Lu 31-130 in Patients With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Lu 31-130 for schizophrenia has completed, reporting efficacy findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lu 31-130

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED